273
Participants
Start Date
May 30, 2019
Primary Completion Date
September 20, 2021
Study Completion Date
September 20, 2021
Escitalopram
8-weeks of treatment followed by 1-week taper down period
Placebo
Matching oral administration of inactive substance once daily
Manhattan Behavioral Medicine PLLC /ID# 233351, New York
Emerson Clinical Research Inst /ID# 233371, Washington D.C.
University of Virginia /ID# 233370, Charlottesville
Coastal Carolina Research Center /ID# 233344, North Charleston
Accel Research Sites-Maitland Clinical Research Unit /ID# 233368, Maitland
Medical Research Group of Central Florida /ID# 233357, Orange City
APG Research, LLC /ID# 233337, Orlando
Innovative Clinical Research /ID# 233365, Fort Lauderdale
Harmonex /ID# 233342, Dothan
Quest Therapeutics of Avon Lake /ID# 233367, Avon Lake
UH Cleveland Medical Center /ID# 233373, Cleveland
Neuro-Behavioral Clinical Research, Inc. /ID# 233375, Canton
CincyScience /ID# 233359, West Chester
University of Cincinnati /ID# 233341, Cincinnati
Midwest Clinical Research Center /ID# 233346, Dayton
Psychiatric Associates /ID# 233360, Overland Park
Woodland International Research Group /ID# 233348, Little Rock
Central States Research /ID# 233339, Tulsa
AIM Trials /ID# 233361, Plano
Relaro Medical Trials /ID# 233369, Dallas
MCB Clinical Research Centers /ID# 233372, Colorado Springs
Northwest Clinical Research Center /ID# 233358, Bellevue
Core Clinical Research /ID# 233353, Everett
Woodland Research Northwest, LLC /ID# 233366, Rogers
ATP Clinical Research, Inc /ID# 233362, Costa Mesa
ProScience Research Group /ID# 233374, Culver City
Sun Valley Research Center /ID# 233343, Imperial
Indago Research and Health Cen /ID# 233364, Hialeah
CNS Healthcare - Jacksonville /ID# 233352, Jacksonville
Clinical Neuroscience Solutions, Inc /ID# 233350, Orlando
University of South Florida Rothman Center of Neuropsychiatry /ID# 233356, St. Petersburg
Capstone Clinical Research /ID# 233354, Libertyville
Baber Research Group /ID# 233363, Naperville
Alivation Research /ID# 233338, Lincoln
Center for Psychiatry and Behavioral Medicine Inc /ID# 233355, Las Vegas
Finger Lakes Clinical Research /ID# 233347, Rochester
SP Research, PLLC /ID# 233340, Oklahoma City
Houston Clinical Trials /ID# 233345, Bellaire
Focus Center, PC /ID# 233349, Ogden
Lead Sponsor
AbbVie
INDUSTRY